Last reviewed · How we verify
BAT4406F Injection
BAT4406F Injection is a monoclonal antibody targeting CD47.
BAT4406F Injection is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | BAT4406F Injection |
|---|---|
| Sponsor | Bio-Thera Solutions |
| Drug class | CD47 antibody |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CD47 is a protein that inhibits phagocytosis, and by targeting it, BAT4406F Injection aims to enhance the body's ability to eliminate cancer cells. This mechanism is based on the principle of blocking the 'don't eat me' signal, allowing the immune system to recognize and destroy cancer cells more effectively.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders (PHASE2)
- A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |